Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (161-170 of 868) with videos related to

Pageof 87
Sort By:
British Journal of Haematology|May 12, 2018
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myelomaCindy Varga, Jacob P Laubach, Kenneth C Anderson, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancer Cell|November 16, 2004
Focus on multiple myelomaConstantine S Mitsiades, Nicholas Mitsiades, Nikhil C Munshi, et al.
Seminars in Oncology|April 30, 2003
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasiasConstantine S Mitsiades, Nicholas Mitsiades, Steven P Treon, et al.
Best Practice & Research. Clinical Haematology|July 20, 2005
Novel biological therapies for the treatment of multiple myelomaPaul G Richardson, Constantine S Mitsiades, Teru Hideshima, et al.
Blood|February 2, 2013
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapyPeter M Voorhees, Jacob Laubach, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
IgD and IgE variants of myeloma: valuable insights and therapeutic opportunitiesPaul G Richardson, Jacob Laubach, Claudia Paba-Prada, et al.
Oncogene|September 7, 2021
Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Blood|April 20, 2004
Advances in biology of multiple myeloma: clinical applicationsTeru Hideshima, P Leif Bergsagel, W Michael Kuehl, et al.
Molecular Cancer Therapeutics|April 14, 2005
Proteasome inhibitor therapy in multiple myelomaDharminder Chauhan, Teru Hideshima, Constantine Mitsiades, et al.
Pageof 87

Showing results (161-170 of 868) with videos related to

Sort By:
Pageof 87
British Journal of Haematology|May 12, 2018
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myelomaCindy Varga, Jacob P Laubach, Kenneth C Anderson, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancer Cell|November 16, 2004
Focus on multiple myelomaConstantine S Mitsiades, Nicholas Mitsiades, Nikhil C Munshi, et al.
Seminars in Oncology|April 30, 2003
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasiasConstantine S Mitsiades, Nicholas Mitsiades, Steven P Treon, et al.
Best Practice & Research. Clinical Haematology|July 20, 2005
Novel biological therapies for the treatment of multiple myelomaPaul G Richardson, Constantine S Mitsiades, Teru Hideshima, et al.
Blood|February 2, 2013
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapyPeter M Voorhees, Jacob Laubach, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
IgD and IgE variants of myeloma: valuable insights and therapeutic opportunitiesPaul G Richardson, Jacob Laubach, Claudia Paba-Prada, et al.
Oncogene|September 7, 2021
Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Blood|April 20, 2004
Advances in biology of multiple myeloma: clinical applicationsTeru Hideshima, P Leif Bergsagel, W Michael Kuehl, et al.
Molecular Cancer Therapeutics|April 14, 2005
Proteasome inhibitor therapy in multiple myelomaDharminder Chauhan, Teru Hideshima, Constantine Mitsiades, et al.
Pageof 87